Abstract
Since its introduction to the US in 1981, In vitro fertilization (IVF) has facilitated the birth of over 1.5 million Americans, largely evading political controversy. This avoidance of political controversy was upended after the judicial interpretation of Alabama’s Wrongful Death of a Minor Act that deemed embryos “unborn children” in early 2024. This decision has sparked a national dialog on IVF, leading to significant legislative efforts at the national level such as the Right to IVF Act, which aims to establish and protect the right to fertility treatment, ensure insurance coverage, and expand access for veterans and marginalized communities. This article examines these legislative initiatives and their potential impacts on the future of IVF in the United States. In addition, it explores the crucial role of primary care clinicians (PCPs) in this evolving landscape, highlighting their importance in patient education, initial fertility assessments, and ongoing support throughout the IVF journey. As the first point of contact for many patients, PCPs are uniquely positioned to navigate the changing legal and ethical considerations surrounding IVF, making their understanding of these developments essential for comprehensive patient care.
- Alabama
- Bioethics
- Endocrinology
- In Vitro Fertilization
- Infertility
- Medical Ethics
- Medical Legislation
- Patient Care
- Primary Health Care
- Reproductive Health
- Reproduction Rights
Since its introduction to the US in 1981, over 1.5 million Americans were conceived and born via In Vitro Fertilization (IVF).1 Until recently, that is, for over 40 years, IVF has largely avoided the political limelight. However, this is no longer the case since February 2024, at which point the Supreme Court of Alabama ruled that embryos created through IVF are to be deemed “unborn children” and thus subject to Alabama’s Wrongful Death of a Minor Act. The ramifications of this ruling, if enforced, could stifle the future practice of IVF within and possibly outside the state of Alabama. Notably, however, the local impact of the aforementioned judicial decision was not fully realized since Alabama governor Kay E. Ivey took it on herself to promptly sign into law legislation that ensures that families in the throes of IVF as well as the caregivers thereof are not to be prosecuted. The national attention received by the Alabama ruling, however, brought to light the absence of current federal legislation assuring access to IVF and to other Assisted Reproductive Technologies (ART). In an effort to redress this legal void, several senators have recently seen to the introduction of bills intent on broadening access to IVF and on the protection thereof. The bills in question include the Veteran Families Health Services Act of 2023 [Sen. Patty L. Murray (D-WA)], the Access to Fertility Treatment and Care Act [Sen. Cory A. Booker (D-NJ)], and the Access to Family Building Act and Family Friendly FEHB Fairness Act [Sen. Tammy L. Duckworth (D-IL)].2 More recently, the aforementioned Senators saw to the unification of their separate efforts in the Right to IVF Act that has recently come up for a vote in the US Senate.2 In this Commentary we review the aforementioned bills as well as assess the future legislative impact thereof on the practice of IVF. For primary care clinicians (PCPs), understanding these legislative developments is crucial as they are often the first point of contact for patients seeking information about fertility treatments. PCPs play a vital role in educating patients about their reproductive options and rights, and these proposed changes could significantly impact the advice and guidance they provide.
Title I of the Right to IVF Act establishes the right “to seek and receive fertility treatment, including ART services.”3 In addition, the bill affords protection to clinicians who offer these services “without States enacting harmful or unwarranted limitations or requirements.”3 In addition, the bill authorizes the United States Department of Justice to initiate legal proceedings to enforce the rights afforded by this legislation.3 Moreover, individuals who believe that their newfound rights have been violated will be entitled to bring legal action to ensure that the rights in question are being upheld.3
Title II of the proposed legislation concerns the rights of active duty service members as well as the provision of ART care to veterans. Specifically, as per the proposed bill, service members will be afforded the opportunity to cryopreserve their gametes before any deployment to a combat zone or if and when assigned to hazardous duty. Service members will also be able to access IVF in the wake of service-related illness or injury. In addition, both veterans and service members will enjoy improved and expanded fertility treatment and counseling options during or after the time of their service. Moreover, research designed “to improve the ability of the Department of Veterans Affairs to meet the long-term reproductive health care needs of veterans” will be bolstered and expanded.3 PCPs serving military communities or veterans should be aware of these potential changes, as they may need to counsel patients on new fertility preservation options and treatment possibilities. This knowledge will enable PCPs to provide more comprehensive care and guidance to their patients in military service or those who have served.
Title III of the bill in question ensures that “a group health plan or a health insurance issuer offering group or individual health insurance coverage” will be required to cover ART.3 In addition, Title III of the proposed bill establishes a consistent minimum level of coverage for fertility treatment that all private health insurance plans will be obliged to comply with. This goal will be accomplished, in part, by limiting out-of-pocket expenditures otherwise imposed by private insurers. In addition, as per the newly crafted bill, State Medicaid plans will be required to underwrite ART coverage nationwide.3 Given the absence of current federal legislation mandating private insurance coverage of ART, coverage of these services by private insurance plans is presently strictly the domain of state legislatures. At the time of this writing, a total of 29 states do not require health care insurers to cover any reproductive services.4 This facet of the bill markedly expands the national coverage of IVF which is presently limited to the 15 states that have enacted IVF coverage mandates.4 A single cycle of IVF ranges in cost from $15,000 to $20,000.4 The average number of IVF cycles leading to conception is 2.5.4 Viewed in this light, Title III of the proposed bill could ensure that the majority of Americans who wish to start a family will have the financial means to do so. For PCPs, these changes in insurance coverage could significantly alter the landscape of fertility treatment recommendations. PCPs may need to familiarize themselves with the new coverage requirements and be prepared to discuss financial aspects of fertility treatments with their patients. This knowledge will enable PCPs to provide more comprehensive counseling on treatment options and help patients navigate the complex world of fertility coverage.
Title IV of the newly proposed bill further promotes the uniformity and broad accessibility of affordable fertility therapy coverage in federal employer-sponsored health insurance plans. Insurance carriers that participate in the Federal Employees Health Benefit (FEHB) Program will be required to cover ART. This provision will improve accessibility to IVF for the over 8 million federal employees who presently are subject to FEHB coverage.2
The potential implications of the passage and enactment of the Right to IVF Act are far-reaching. Faced with a record 40-year low in the national fertility rate in 2023, increased access to fertility services could potentially mitigate this downward trend.5 In addition, this legislation will align the US with European nations wherein the right to IVF and the underwriting thereof is governmentally mandated. The broadening of coverage to include ART could have a positive impact on members of marginalized communities who wish to start a family. Both African Americans and American Indians presently use IVF services at a rate that is lower than the national average.4 Given that the aforementioned minority groups are likely to be disproportionally affected by the requisite financial barriers, the hoped for expanded coverage could bring about more equitable reproductive health outcomes for these populations. Moreover, working women are likely to experience new freedoms that were previously denied to those who could not afford IVF, thus allowing women to pursue their careers without having to choose between professional priorities and the desire to start a family.
The Right to IVF Act was endorsed by RESOLVE: The National Infertility Association, the American Society for Reproductive Medicine, and the Endocrine Society.2 Despite this support and the profamily nature of the bill, the Southern Baptist Convention has recently voted to oppose the legislation which may have played a part in the blockade of the bill by Senate Republicans.6 While the future of the Right to IVF Act remains in question, one thing is clear: the past 40 years during which IVF resided in the “political shadows” are over in that IVF has now become a component of the prolife/prochoice debate.7 Viewed in this light, one can anticipate a growing attention to IVF at the congressional, state, or judicial levels in a manner that could affect the reproductive rights of Americans replete with the prospect of building a family. As the political landscape surrounding IVF continues to evolve, PCPs should stay informed about these developments and be prepared to navigate potentially sensitive discussions with patients. PCPs must be prepared to adapt their practice to these potential changes, staying informed about new coverage options, legal protections, and evolving ethical considerations. By doing so, they can continue to provide comprehensive, patient-centered care in the rapidly changing field of reproductive medicine
Notes
This article was externally peer reviewed.
Funding: No funding was received for this work.
Conflict of interest: The authors have no conflicts of interest to declare.
To see this article online, please go to: http://jabfm.org/content/38/2/345.full.
- Received for publication August 21, 2024.
- Revision received October 28, 2024.
- Accepted for publication November 18, 2024.
